Abstract
In 3 years, 118 patients with Hodgkin's disease have completed chemotherapy with chlorambucil, vinblastine, procarbazine and prednisolone (Ch1VPP). The complete remission rates were 90% for 29 patients previously treated with radiotherapy, 67% for 73 patients previously untreated and 44% for 16 patients with prior chemotherapy. The 3-year survival rates for the first 70 patients in the series were 83% for previously irradiated patients, 84% for previously untreated patients and 67% for those with prior chemotherapy. Forty-seven previously untreated or previously irradiated patients in this group achieved complete remission. The 3-year disease-free survival rates for these patients were 71% and 67% respectively. This regimen gives complete remission and survival rates comparable with results obtained with combinations including nitrogen mustard, while producing fewer side-effects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Kaye, S., Juttner, C., Smith, I. et al. Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease. Br J Cancer 39, 168–174 (1979). https://doi.org/10.1038/bjc.1979.27
Issue Date:
DOI: https://doi.org/10.1038/bjc.1979.27
This article is cited by
-
An effective oral combination in advanced relapsed Hodgkin’s disease prednisolone, etoposide, chlorambucil and CCNU
Cancer Chemotherapy and Pharmacology (1990)
-
Chemotherapy treated hodgkins disease — A fifteen year review
Irish Journal of Medical Science (1986)
-
Stadien IIIB und IVB des Morbus Hodgkin Ansprechbarkeit auf Chemotherapie, Rezidive, Ãœberlebensraten
Klinische Wochenschrift (1981)